keyword
MENU ▼
Read by QxMD icon Read
search

Doi yohei

keyword
https://www.readbyqxmd.com/read/28139431/prevalence-risk-factors-outcomes-and-molecular-epidemiology-of-mcr-1-positive-enterobacteriaceae-in-patients-and-healthy-adults-from-china-an-epidemiological-and-clinical-study
#1
Yang Wang, Guo-Bao Tian, Rong Zhang, Yingbo Shen, Jonathan M Tyrrell, Xi Huang, Hongwei Zhou, Lei Lei, Hong-Yu Li, Yohei Doi, Ying Fang, Hongwei Ren, Lan-Lan Zhong, Zhangqi Shen, Kun-Jiao Zeng, Shaolin Wang, Jian-Hua Liu, Congming Wu, Timothy R Walsh, Jianzhong Shen
BACKGROUND: The mcr-1 gene confers transferable colistin resistance. mcr-1-positive Enterobacteriaceae (MCRPE) have attracted substantial medical, media, and political attention; however, so far studies have not addressed their clinical impact. Herein, we report the prevalence of MCRPE in human infections and carriage, clinical associations of mcr-1-positive Escherichia coli (MCRPEC) infection, and risk factors for MCRPEC carriage. METHODS: We undertook this study at two hospitals in Zhejiang and Guangdong, China...
January 27, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28106103/sox2-and-rb1-in-esophageal-small-cell-carcinoma-their-possible-involvement-in-pathogenesis
#2
Hirotaka Ishida, Atsuko Kasajima, Takashi Kamei, Tsuyoshi Miura, Naomi Oka, Samaneh Yazdani, Yohei Ozawa, Fumiyoshi Fujishima, Akira Sakurada, Yasuhiro Nakamura, Yoichi Tanaka, Masafumi Kurosumi, Yuichi Ishikawa, Yoshinori Okada, Noriaki Ohuchi, Hironobu Sasano
Clinicopathological features and pathogenesis of esophageal small-cell carcinoma remain unclear. We hypothesized common cellular origin and pathogenesis in small-cell carcinoma of esophagus and lung associated with SOX2 overexpression and loss of Rb1. Expression of squamous-basal markers (CK5/6 and p40), glandular markers (CK18 and CEA), SOX2, and Rb1 were evaluated in 15 esophageal small-cell carcinomas, 46 poorly differentiated squamous cell carcinomas, and 88 small-cell lung carcinoma, as well as 16 embryonic esophagus...
January 20, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28098547/mcr-1-harboring-salmonella-enterica-serovar-typhimurium-sequence-type-34-in-pigs-china
#3
Linxian Yi, Jing Wang, Yanling Gao, Yiyun Liu, Yohei Doi, Renjie Wu, Zhenling Zeng, Zisen Liang, Jian-Hua Liu
We detected the mcr-1 gene in 21 (14.8%) Salmonella isolates from pigs at slaughter; 19 were serovar Typhimurium sequence type 34. The gene was located on IncHI2-like plasmids that also harbored IncF replicons and lacked a conjugative transfer region. These findings highlight the need to prevent further spread of colistin resistance in animals and humans.
February 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28031201/emergence-of-ceftazidime-avibactam-resistance-due-to-plasmid-borne-blakpc-3-mutations-during-treatment-of-carbapenem-resistant-klebsiella-pneumoniae-infections
#4
Ryan K Shields, Liang Chen, Shaoji Cheng, Kalyan D Chavda, Ellen G Press, Avin Snyder, Ruchi Pandey, Yohei Doi, Barry N Kreiswirth, M Hong Nguyen, Cornelius J Clancy
Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae (CRE) that produce Klebsiella pneumoniae carbapenemase (KPC). We report the first cases of ceftazidime-avibactam resistance to develop during treatment of CRE infections, and identify resistance mechanisms. Ceftazidime-avibactam resistant K. pneumoniae emerged in three patients after ceftazidime-avibactam treatment for 10-19 days. Whole genome sequencing (WGS) of longitudinal ceftazidime-avibactam susceptible and resistant K...
December 28, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27940944/colistin-resistance-in-carbapenem-resistant-klebsiella-pneumoniae-laboratory-detection-and-impact-on-mortality
#5
Laura J Rojas, Madiha Salim, Eric Cober, Sandra S Richter, Federico Perez, Robert A Salata, Robert C Kalayjian, Richard R Watkins, Steve Marshall, Susan D Rudin, T Nicholas Domitrovic, Andrea M Hujer, Kristine M Hujer, Yohei Doi, Keith S Kaye, Scott Evans, Vance G Fowler, Robert A Bonomo, David van Duin
BACKGROUND: Polymyxins including colistin are an important "last-line" treatment for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKp). Increasing use of colistin has led to resistance to this cationic antimicrobial peptide. METHODS: A cohort nested within the Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRACKLE) was constructed of patients with infection, or colonization with CRKp isolates tested for colistin susceptibility during the study period of December, 2011 to October, 2014...
December 10, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27923418/outbreak-of-klebsiella-pneumoniae-carbapenemase-producing-citrobacter-freundii-at-a-tertiary-acute-care-facility-in-miami-florida
#6
Adriana Jiménez, José G Castro, L Silvia Munoz-Price, Dennise de Pascale, Luis Shimose, Mustapha M Mustapha, Caressa N Spychala, Roberta T Mettus, Vaughn S Cooper, Yohei Doi
OBJECTIVE To describe the investigation and control of a rare cluster of Klebsiella pneumoniae carbapenemase-producing Citrobacter freundii in a hospital in southern Florida. METHODS An epidemiologic investigation, review of infection prevention procedures, and molecular studies including whole genome sequencing were conducted. RESULTS An outbreak of K. pneumoniae carbapenemase-3-producing C. freundii was identified at a tertiary hospital in Florida in 2014. Of the 6 cases identified, 3 occurred in the same intensive care unit and were caused by the same clone...
December 7, 2016: Infection Control and Hospital Epidemiology
https://www.readbyqxmd.com/read/27866488/disposable-bronchoscope-model-for-simulating-endoscopic-reprocessing-and-surveillance-cultures
#7
Mohamed H Yassin, Rahman Hariri, Yasir Hamad, Juliet Ferrelli, Leeanna McKibben, Yohei Doi
BACKGROUND Endoscope-associated infections are reported despite following proper reprocessing methods. Microbiological testing can confirm the adequacy of endoscope reprocessing. Multiple controversies related to the method and interpretation of microbiological testing cultures have arisen that make their routine performance a complex target. OBJECTIVE We conducted a pilot study using disposable bronchoscopes (DBs) to simulate different reprocessing times and soaking times and to compare high-level disinfection versus ethylene oxide sterilization...
February 2017: Infection Control and Hospital Epidemiology
https://www.readbyqxmd.com/read/27830191/comparative-genome-analysis-of-extended-spectrum-%C3%AE-lactamase-producing-escherichia-coli-sequence-type-131-strains-from-nepal-and-japan
#8
Tohru Miyoshi-Akiyama, Jatan Bahadur Sherchan, Yohei Doi, Maki Nagamatsu, Jeevan B Sherchand, Sarmila Tandukar, Norio Ohmagari, Teruo Kirikae, Hiroshi Ohara, Kayoko Hayakawa
The global spread of extended-spectrum-β-lactamase (ESBL)-producing Escherichia coli (ESBL-E. coli) has largely been driven by the pandemic sequence type 131 (ST131). This study aimed to determine the molecular epidemiology of their spread in two Asian countries with contrasting prevalence. We conducted whole-genome sequencing (WGS) of ESBL-E. coli ST131 strains collected prospectively from Nepal and Japan, two countries in Asia with a high and low prevalence of ESBL-E. coli, respectively. We also systematically compared these genomes with those reported from other regions using publicly available WGS data for E...
September 2016: MSphere
https://www.readbyqxmd.com/read/27828759/prevalence-of-extended-spectrum-%C3%AE-lactamases-ctx-m-8-and-ctx-m-2-producing-salmonella-serotypes-from-clinical-and-nonhuman-isolates-in-brazil
#9
Sueli Aparecida Fernandes, Carlos Henrique Camargo, Gabriela Rodrigues Francisco, Maria Fernanda Campagnari Bueno, Doroti Oliveira Garcia, Yohei Doi, Monique Ribeiro Tiba Casas
We characterized extended-spectrum β-lactamases (ESBL) enzymes among Salmonella strains isolated in Brazil from 2009 to 2014. Salmonella recovered from both clinical and nonhuman (food, poultry, and environment) sources were subjected to antimicrobial susceptibility testing. β-lactamases genes were detected by polymerase chain reaction/sequencing; plasmid profiles and transferability were assessed by S1-pulsed field gel electrophoresis (PFGE). Genetic diversity was evaluated by XbaI-PFGE. Out of 630 Salmonella strains screened, 46 displayed ESBL phenotype, distributed across 11 different serotypes...
November 9, 2016: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/27821458/coproduction-of-mcr-1-and-ndm-1-by-colistin-resistant-escherichia-coli-isolated-from-a-healthy-individual
#10
LETTER
Lan-Lan Zhong, Yan-Fen Zhang, Yohei Doi, Xi Huang, Xue-Fei Zhang, Kun-Jiao Zeng, Cong Shen, Sandip Patil, Yong Xing, Yutian Zou, Guo-Bao Tian
No abstract text is available yet for this article.
January 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27810466/proposed-primary-endpoints-for-use-in-clinical-trials-that-compare-treatment-options-for-bloodstream-infection-in-adults-a-consensus-definition
#11
REVIEW
Patrick N A Harris, John F McNamara, David C Lye, Joshua S Davis, Louis Bernard, Allen C Cheng, Yohei Doi, Vance G Fowler, Keith S Kaye, Leonard Leibovici, Jeffrey Lipman, Martin J Llewelyn, Silvia Munoz-Price, Mical Paul, Anton Y Peleg, Jesús Rodríguez-Baño, Benjamin A Rogers, Harald Seifert, Visanu Thamlikitkul, Guy Thwaites, Steven Y C Tong, John Turnidge, Riccardo Utili, Steven A R Webb, David L Paterson
OBJECTIVES: To define standardised endpoints to aid the design of trials that compare antibiotic therapies for bloodstream infection (BSI). METHODS: Prospective studies, randomised trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Consensus endpoints for BSI studies were defined using a modified Delphi process. RESULTS: Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI...
October 31, 2016: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/27747047/early-or-delayed-initiation-of-renal-replacement-therapy-for-critically-ill-patients-do-we-know-the-right-time
#12
COMMENT
Yohei Komaru, Kent Doi
No abstract text is available yet for this article.
September 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27712635/a-predictive-model-of-mortality-in-patients-with-bloodstream-infections-due-to-carbapenemase-producing-enterobacteriaceae
#13
Belén Gutiérrez-Gutiérrez, Elena Salamanca, Marina de Cueto, Po-Ren Hsueh, Pierluigi Viale, José Ramón Paño-Pardo, Mario Venditti, Mario Tumbarello, George Daikos, Vicente Pintado, Yohei Doi, Felipe Francisco Tuon, Ilias Karaiskos, Isabel Machuca, Mitchell J Schwaber, Özlem Kurt Azap, Maria Souli, Emmanuel Roilides, Spyros Pournaras, Murat Akova, Federico Pérez, Joaquín Bermejo, Antonio Oliver, Manel Almela, Warren Lowman, Benito Almirante, Robert A Bonomo, Yehuda Carmeli, David L Paterson, Alvaro Pascual, Jesús Rodríguez-Baño
OBJECTIVE: To develop a score to predict mortality in patients with bloodstream infections (BSIs) due to carbapenemase-producing Enterobacteriaceae (CPE). PATIENTS AND METHODS: A multinational retrospective cohort study (INCREMENT project) was performed from January 1, 2004, through December 31, 2013. Patients with clinically relevant monomicrobial BSIs due to CPE were included and randomly assigned to either a derivation cohort (DC) or a validation cohort (VC)...
October 2016: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/27683817/cd36-provides-host-protection-against-klebsiella-pneumoniae-intrapulmonary-infection-by-enhancing-lipopolysaccharide-responsiveness-and-macrophage-phagocytosis
#14
Tolani F Olonisakin, Huihua Li, Zeyu Xiong, Elizabeth J K Kochman, Minting Yu, Yanyan Qu, Mei Hulver, Jay K Kolls, Claudette St Croix, Yohei Doi, Minh-Hong Nguyen, Robert M Q Shanks, Rama K Mallampalli, Valerian E Kagan, Anuradha Ray, Roy L Silverstein, Prabir Ray, Janet S Lee
Klebsiella pneumoniae remains an important cause of intrapulmonary infection and invasive disease worldwide. K. pneumoniae can evade serum killing and phagocytosis primarily through the expression of a polysaccharide capsule, but its pathogenicity is also influenced by host factors. We examined whether CD36, a scavenger receptor that recognizes pathogen and modified self ligands, is a host determinant of K. pneumoniae pathogenicity. Despite differences in serum sensitivity and virulence of 3 distinct K. pneumoniae (hypermucoviscous K1, research K2, and carbapenemase-producing ST258) strains, the absence of CD36 significantly increased host susceptibility to acute intrapulmonary infection by K...
December 15, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27681484/the-pharmacokinetics-of-beraprost-sodium-following-single-oral-administration-to-subjects-with-impaired-kidney-function
#15
Masahiro Shimamura, Jun Miyakawa, Masaaki Doi, Kiyonobu Okada, Hajimu Kurumatani, Yoshitaka Mori, Keiyu Oshida, Ikumi Nakajo, Keishi Oikawa, Fumihiko Ushigome, Aiji Miyashita, Masanao Isono, Yohei Miyamoto
The purpose of the present study was to evaluate the pharmacokinetics of beraprost sodium (BPS) and its active enantiomer, BPS-314d, in Japanese subjects with impaired kidney function. The plasma and urine concentrations of BPS and BPS-314d were measured following the single oral administration of 120 μg of BPS as the sustained-release tablet, TRK-100STP, under fasting conditions to 18 subjects with impaired kidney function (stage 2, 3, and 4 chronic kidney disease (CKD) (as categorized by the estimated glomerular filtration rate)) and to 6 age-, body weight-, and gender-matched subjects with normal kidney function (stage 1 CKD)...
September 28, 2016: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27629901/comparison-of-minocycline-susceptibility-testing-methods-for-carbapenem-resistant-acinetobacter-baumannii
#16
Peng Wang, Sarah L Bowler, Serena F Kantz, Roberta T Mettus, Yan Guo, Christi L McElheny, Yohei Doi
Treatment options for infections due to carbapenem-resistant Acinetobacter baumannii are extremely limited. Minocycline is a semisynthetic tetracycline derivative with activity against this pathogen. This study compared susceptibility testing methods that are used in clinical microbiology laboratories (Etest, disk diffusion, and Sensititre broth microdilution methods) for testing of minocycline, tigecycline, and doxycycline against 107 carbapenem-resistant A. baumannii clinical isolates. Susceptibility rates determined with the standard broth microdilution method using cation-adjusted Mueller-Hinton (MH) broth were 77...
December 2016: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/27626100/an-unlikely-pair-the-antimicrobial-synergy-of-polymyxin-b-in-combination-with-the-cystic-fibrosis-transmembrane-conductance-regulator-drugs-kalydeco-and-orkambi
#17
Elena K Schneider, Mohammad A K Azad, Mei-Ling Han, Qi Tony Zhou, Jiping Wang, Johnny X Huang, Matthew A Cooper, Yohei Doi, Mark A Baker, Phillip J Bergen, Mark T Muller, Jian Li, Tony Velkov
Novel combination therapies are desperately needed for combating lung infections caused by bacterial "superbugs". This study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with the cystic fibrosis (CF) drugs KALYDECO (ivacaftor) and ORKAMBI (ivacaftor + lumacaftor) against Gram-negative pathogens that commonly colonize the CF lung, in particular, the problematic Pseudomonas aeruginosa. The in vitro synergistic activity of polymyxin B combined with ivacaftor or lumacaftor was assessed using checkerboard and static time-kill assays against a panel of polymyxin-susceptible and polymyxin-resistant P...
July 8, 2016: ACS Infectious Diseases
https://www.readbyqxmd.com/read/27624958/clinical-outcomes-drug-toxicity-and-emergence-of-ceftazidime-avibactam-resistance-among-patients-treated-for-carbapenem-resistant-enterobacteriaceae-infections
#18
Ryan K Shields, Brian A Potoski, Ghady Haidar, Binghua Hao, Yohei Doi, Liang Chen, Ellen G Press, Barry N Kreiswirth, Cornelius J Clancy, M Hong Nguyen
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.
December 15, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27593176/the-global-epidemiology-of-carbapenemase-producing-enterobacteriaceae
#19
David van Duin, Yohei Doi
Carbapenemase-producing Enterobacteriaceae (CPE) are an important and increasing threat to global health. Both clonal spread and plasmid-mediated transmission contribute to the ongoing rise in incidence of these bacteria. Among the 4 classes of β-lactamases defined by the Ambler classification system, the carbapenemases that confer carbapenem resistance in Enterobacteriaceae belong to 3 of them: Class A (K. pneumoniae carbapenemases, KPC), Class B (metallo-β-lactamases, MBL including New Delhi metallo-β-lactamases, NDM) and Class D (OXA-48-like carbapenemases)...
August 11, 2016: Virulence
https://www.readbyqxmd.com/read/27572405/characterization-of-a-novel-inchi2-plasmid-carrying-tandem-copies-of-blactx-m-2-in-a-fosa6-harboring-escherichia-coli-sequence-type-410-strain
#20
Qinglan Guo, Baixing Ding, Thomas Jové, Nicole Stoesser, Vaughn S Cooper, Minggui Wang, Yohei Doi
The extended-spectrum β-lactamase gene blaCTX-M-2 is mainly associated with ISCR1 embedded in complex sul1-type integrons, but information on the genetic context of plasmids harboring the ISCR1-blaCTX-M-2 module remains limited. In this study, a blaCTX-M-2-harboring plasmid (pYD786-1) belonging to the sequence type 2 (ST2)-IncHI2 plasmid type and isolated from an Escherichia coli ST410 clinical strain was sequenced and analyzed. pYD786-1 belongs to the APEC-O1-R-type IncHI2 plasmids, which are widely distributed in human, poultry, and livestock strains...
November 2016: Antimicrobial Agents and Chemotherapy
keyword
keyword
30721
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"